2023 World Conference on Lung Cancer (Posters)-P2.12. Beware: Tyrosine Kinase Inhibitors for Lung Cancers that Inhibit MATE-1 can Lead to "False” Decreases in Renal Function

P2.12. Beware: Tyrosine Kinase Inhibitors for Lung Cancers that Inhibit MATE-1 can Lead to "False” Decreases in Renal Function - PDF(Slides)

Back to course

Pdf Summary

This document discusses the limitations of creatinine as a marker for measuring renal function and suggests an alternative marker called cystatin C. Creatinine is commonly used in clinical practice but is not a perfect indicator of renal function. The document explains that certain inhibitors of a transporter called MATE-1, which is found in renal proximal tubule cells, can reduce creatinine clearance and lead to false decreases in renal function.<br /><br />The document focuses on tyrosine kinase inhibitors (TKIs) used to treat lung cancer, which are known to be MATE inhibitors. It states that patients receiving MATE inhibitors may be falsely interpreted as developing kidney injury, leading to unnecessary holds and dose reductions of important anticancer therapy.<br /><br />The researchers analyzed data from patients with non-small cell lung cancer who received treatment with a known MATE inhibitor at Memorial Sloan Kettering Cancer Center. They used the Kidney Disease: Improving Global Outcomes criteria for acute kidney injury to assess renal function. Cystatin C measurements were also taken when available.<br /><br />The results showed that in 96% of cases, cystatin C corresponded to improved renal function compared to creatinine. The document concludes that cystatin C may be a better estimator of kidney function in patients on MATE inhibitors and suggests that using cystatin C as an alternative marker could prevent unnecessary holds and dose reductions of anticancer therapy in these patients.<br /><br />Overall, this study highlights the potential limitations of using creatinine as a marker for renal function in patients receiving MATE inhibitors and proposes cystatin C as a more reliable alternative.

Asset Subtitle

Monica Chen

Meta Tag

Speaker Monica Chen

Topic Metastatic NSCLC: Targeted Therapy - Other

Keywords

creatinine

renal function

cystatin C

marker

limitations

MATE-1

tyrosine kinase inhibitors

lung cancer

kidney injury

anticancer therapy